Patents by Inventor David B. Rozema
David B. Rozema has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220079973Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: ApplicationFiled: November 17, 2021Publication date: March 17, 2022Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen LI, Rui ZHU, Christine I. WOODDELL, Bruce D. GIVEN, Tao PEI, David L. LEWIS, Lauren J. ALMEIDA, David B. ROZEMA, Darren H. WAKEFIELD
-
Patent number: 11174480Abstract: Described are post transcriptionally chemically modified double strand RNAs (MdsRNAs) having more than 30 base pairs. The MdsRNAs inhibit gene expression in target organisms. Also described are methods of making and using MdsRNAs.Type: GrantFiled: October 22, 2018Date of Patent: November 16, 2021Assignee: nanoSUR LLCInventors: Juan P. Arhancet, Sreevishnu Cheerla, Graciela B. Arhancet, David B. Rozema
-
Publication number: 20210189394Abstract: Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to an expression-inhibiting oligomeric compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.Type: ApplicationFiled: February 24, 2021Publication date: June 24, 2021Inventors: David B Rozema, Darren H. Wakefield, Andrei V. Blokhin, Jonathan D. Benson, Zhen Li, Tao Pei, Fred Fleitz
-
Publication number: 20210180066Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.Type: ApplicationFiled: February 19, 2021Publication date: June 17, 2021Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
-
Publication number: 20210100829Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: ApplicationFiled: August 11, 2020Publication date: April 8, 2021Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen LI, Rui ZHU, Christine I. WOODDELL, Bruce D. GIVEN, Tao PEI, David L. LEWIS, Lauren J. ALMEIDA, David B. ROZEMA, Darren H. WAKEFIELD
-
Publication number: 20210052624Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment.Type: ApplicationFiled: September 9, 2020Publication date: February 25, 2021Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Christine I. WOODDELL, David B. ROZEMA, David L. LEWIS, Darren H. WAKEFIELD, Lauren J. ALMEIDA
-
Patent number: 10927373Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.Type: GrantFiled: April 16, 2018Date of Patent: February 23, 2021Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
-
Patent number: 10806750Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment.Type: GrantFiled: October 1, 2018Date of Patent: October 20, 2020Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Christine I. Wooddell, David B. Rozema, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
-
Patent number: 10780108Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: GrantFiled: August 4, 2017Date of Patent: September 22, 2020Assignee: ARROWHEAD PHARMACEUTICALS, INC.Inventors: Zhen Li, Rui Zhu, Christine Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
-
Publication number: 20200263179Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.Type: ApplicationFiled: May 6, 2020Publication date: August 20, 2020Inventors: Stacey MELQUIST, Steven KANNER, David B. ROZEMA, David L. LEWIS, Lauren J. ALMEIDA, Darren H. WAKEFIELD, Vladimir S. TRUBETSKOY, Tao PEI, Zhen LI, Aaron ALMEIDA
-
Patent number: 10662427Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.Type: GrantFiled: February 21, 2018Date of Patent: May 26, 2020Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Stacey Melquist, Steven Kanner, David B. Rozema, David L. Lewis, Lauren J. Almeida, Darren H. Wakefield, Vladimir S. Trubetskoy, Tao Pei, Zhen Li, Aaron Almeida
-
Patent number: 10640769Abstract: Described are post transcriptionally chemically modified double strand RNAs (MdsRNAs) having more than 30 base pairs. The MdsRNAs inhibit gene expression in target organisms. Also described are methods of making and using MdsRNAs.Type: GrantFiled: October 22, 2018Date of Patent: May 5, 2020Assignee: nanoSUR LLCInventors: Juan P. Arhancet, Sreevishnu Cheerla, Graciela B. Arhancet, David B. Rozema
-
Publication number: 20190292547Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: ApplicationFiled: August 4, 2017Publication date: September 26, 2019Inventors: Zhen Li, Rui Zhu, Christine Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
-
Publication number: 20190255091Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: ApplicationFiled: February 4, 2019Publication date: August 22, 2019Applicant: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
-
Publication number: 20190211333Abstract: Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to an expression-inhibiting oligomeric compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.Type: ApplicationFiled: March 25, 2019Publication date: July 11, 2019Inventors: David B. Rozema, Darren H. Wakefield, Andrei V. Blokhin, Jonathan D. Benson, Zhen Li, Tao Pei, Fred Fleitz
-
Patent number: 10316316Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.Type: GrantFiled: April 19, 2016Date of Patent: June 11, 2019Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: David L Lewis, David B Rozema, Darren H Wakefield, Torsten Hoffman, Erik Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
-
Patent number: 10246709Abstract: Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to an expression-inhibiting oligomeric compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.Type: GrantFiled: March 7, 2017Date of Patent: April 2, 2019Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: David B. Rozema, Darren H. Wakefield, Andrei V. Blokhin, Jonathan D. Benson, Zhen Li, Tao Pei, Fred Fleitz
-
Publication number: 20190062748Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) triggers to integrin positive tumor cells in vivo. The compositions comprise RGD ligand-targeted amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or conjugate) are further covalently linked to an RNAi trigger.Type: ApplicationFiled: November 13, 2018Publication date: February 28, 2019Inventors: David B. Rozema, So Wong, Weijun Cheng, Aaron M. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson
-
Publication number: 20190048345Abstract: Described are post transcriptionally chemically modified double strand RNAs (MdsRNAs) having more than 30 base pairs. The MdsRNAs inhibit gene expression in target organisms. Also described are methods of making and using MdsRNAs.Type: ApplicationFiled: October 22, 2018Publication date: February 14, 2019Inventors: Juan P. Arhancet, Sreevishnu Cheerla, Graciela B. Arhancet, David B. Rozema
-
Publication number: 20190040389Abstract: Described are post transcriptionally chemically modified double strand RNAs (MdsRNAs) having more than 30 base pairs. The MdsRNAs inhibit gene expression in target organisms. Also described are methods of making and using MdsRNAs.Type: ApplicationFiled: October 22, 2018Publication date: February 7, 2019Inventors: Juan P. Arhancet, Sreevishnu Cheerla, Graciela B. Arhancet, David B. Rozema